COGNITION THERAPEUTICS INC
CGTX$18M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaPURCHASE25 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
Aug 6, 2026
6wMarket Overview
Stock performance and key metrics
CGTX News
Catalyst Timeline
3 upcoming, 0 past
Drug Pipeline
CT1812
Early Alzheimer's Disease
C105
Cognition Disorders
golexanolone
Primary Biliary Cholangitis (PBC)
Active Treatment- CT1812 100 mg
Alzheimer Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CT1812 | Phase 2 | Early Alzheimer's Disease | - | - |
C105 | Phase 2 | Cognition Disorders | - | - |
golexanolone | Phase 2 | Primary Biliary Cholangitis (PBC) | - | - |
Active Treatment- CT1812 100 mg | Phase 2 | Alzheimer Disease | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply